Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Johnson & Johnson (JNJ) Price & Performance

Global X Artificial Intelligence & Technology ETFTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Global X Artificial Intelligence & Technology ETF vs Johnson & Johnson — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.79, while Johnson & Johnson trades at $260.86 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.

AIQJNJ
Sector
Sector/ThematicHealth
52-Week High
$70.14$267.24
52-Week Low
$43.88$172.78
Market Cap
$626.09B
Volume
6,156,228
Enterprise Value
$654.37B
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Artificial Intelligence & Technology ETF

AIQ (Global X Artificial Intelligence & Technology ETF) trades at $63.77, up 0.41% with strong bullish momentum. Technical indicators show the stock above key moving averages with RSI suggesting mild overbought conditions. Recent news highlights AIQ's outperformance versus the Nasdaq, gaining 25% while attracting attention as a diversified AI play beyond semiconductor stocks. The ETF's systematic rebalancing approach positions it well for the evolving AI investment landscape.

AIQ offers exposure to the growing artificial intelligence sector with reduced single-stock risk. Key catalysts include upcoming AI company IPOs and federal quantum computing funding. Risks include thematic ETF volatility and premium fees compared to broader indices. The stock's proximity to resistance levels near $64 suggests potential near-term consolidation before further upside.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Artificial Intelligence & Technology ETF

AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.

Read more on AIQ

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ